5 min. read

Quick data scan on federal contracts. Rethinking platform strategies.

Issue 017.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 74 percent open rate. Here's what's happening this week:

  • The late arrival of your weekly newsletter follows a 24-hour, feverish flu afflicting the entire editorial staff -- absolutely everyone -- at E&O.
  • Big news for ResApp: The Australia-based DTx secured a CE Mark for its first commercial product ResAppDx-EU, as a Class IIa medical device. "ResAppDx-EU is a mobile software application to be used by clinicians for the diagnosis of lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease and bronchiolitis in infants and children."
  • Israel-based BioBeat Technologies received FDA clearance for its cuffless, blood pressure device, which already has clearance for pulse oximetry. Still waiting for the summary document to hit the FDA

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles